{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:01:13Z","timestamp":1786114873429,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jsbmb.2026.107062","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:38:13Z","timestamp":1782747493000},"page":"107062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Androgen receptor as therapeutic indicator for LAR-positive triple-negative breast cancer: Preclinical and clinical assessment"],"prefix":"10.1016","volume":"263","author":[{"given":"Nirali","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanshi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshikha","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandani","family":"Dharwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemangini","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigna","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-6515","authenticated-orcid":false,"given":"Heena","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jsbmb.2026.107062_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/oncolo\/oyad049","article-title":"Revisiting androgen receptor signaling in breast cancer","volume":"28","author":"Dai","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.jsbmb.2026.107062_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405491","article-title":"Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies","volume":"14","author":"Xiong","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107062_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.836417","article-title":"Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence","volume":"9","author":"Almansour","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107062_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: promising prognostic biomarkers currently in development","volume":"21","author":"Sukumar","year":"2021","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4174\/astr.2023.104.1.1","article-title":"Prognosis according to the timing of recurrence in breast cancer","volume":"104","author":"Lee","year":"2023","journal-title":"Ann. Surg. Treat. Res."},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107062_bib6","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107062_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102993","article-title":"Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin","volume":"9","author":"Hu","year":"2024","journal-title":"ESMO Open."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-022-01574-4","article-title":"Androgen receptor function and targeted therapeutics across breast cancer subtypes","volume":"24","author":"Kolyvas","year":"2022","journal-title":"Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.jsbmb.2026.107062_bib9","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-17-1912","article-title":"Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann\u2019s refined classification","volume":"24","author":"Echavarria","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107062_bib10","doi-asserted-by":"crossref","first-page":"vi55","DOI":"10.1093\/annonc\/mdw364.43","article-title":"Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer","volume":"27","author":"Chica-Parrado","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107062_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117473","article-title":"Therapeutic prospects of sex hormone receptor signaling in hormone-responsive cancers","volume":"180","author":"Boye","year":"2024","journal-title":"Biomed. & Pharmacother."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107062_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41568-024-00772-w","article-title":"Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities","volume":"25","author":"Dotto","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107062_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2019.05.005","article-title":"Consideration of breast cancer subtype in targeting the androgen receptor","volume":"200","author":"Venema","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib15","first-page":"3","article-title":"Androgen receptor structure, function and biology: from bench to bedside","volume":"37","author":"Davey","year":"2016","journal-title":"Clin. Biochem. Rev."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107062_bib16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5534\/wjmh.180040","article-title":"Role of Androgen Receptor in Prostate Cancer: A Review","volume":"37","author":"Fujita","year":"2019","journal-title":"World J. Mens. Health"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12958-024-01338-z","article-title":"Looking beyond the ER, PR, and HER2: what\u2019s new in the ARsenal for combating breast cancer?","volume":"23","author":"Srivastava","year":"2025","journal-title":"Reprod. Biol. Endocrinol."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12935-024-03313-5","article-title":"Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy","volume":"24","author":"Zhao","year":"2024","journal-title":"Cancer Cell. Int."},{"issue":"19","key":"10.1016\/j.jsbmb.2026.107062_bib19","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor\u2013positive, estrogen receptor\u2013negative metastatic breast cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107062_bib20","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor\u2013expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107062_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122697","article-title":"Androgen receptor: Structure, signaling, function and potential drug discovery biomarker in different breast cancer subtypes","author":"Shukla","year":"2024","journal-title":"Life Sci."},{"issue":"17","key":"10.1016\/j.jsbmb.2026.107062_bib22","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-15-0381","article-title":"Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes","volume":"75","author":"Xu","year":"2015","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107062_bib23","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-11-0141","article-title":"Alternatively spliced androgen receptor variants","volume":"18","author":"Dehm","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107062_bib24","doi-asserted-by":"crossref","first-page":"T199","DOI":"10.1530\/ERC-16-0298","article-title":"Emerging data on androgen receptor splice variants in prostate cancer","volume":"23","author":"Cao","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajur.2018.07.003","article-title":"Current strategies for targeting the activity of androgen receptor variants","volume":"6","author":"Armstrong","year":"2019","journal-title":"Asian J. Urol."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107062_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12672-014-0171-4","article-title":"Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues","volume":"5","author":"Hu","year":"2014","journal-title":"Horm. Cancer"},{"issue":"42","key":"10.1016\/j.jsbmb.2026.107062_bib27","doi-asserted-by":"crossref","first-page":"44728","DOI":"10.18632\/oncotarget.6296","article-title":"Expression of androgen receptor splice variants in clinical breast cancers","volume":"6","author":"Hickey","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107062_bib28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3892\/ol.2011.375","article-title":"Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies","volume":"2","author":"Vranic","year":"2011","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107062_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0959-8049(94)90424-3","article-title":"MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression","volume":"30","author":"Hall","year":"1994","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3599","article-title":"Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide","volume":"16","author":"Cochrane","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107062_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/117822341000400004","article-title":"The expression patterns of ER, PR, HER2, CK5\/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines","volume":"4","author":"Subik","year":"2010","journal-title":"Breast Cancer (Auckl)"},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107062_bib32","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00432-019-02872-9","article-title":"Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer","volume":"145","author":"Anestis","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107062_bib33","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.7150\/ijbs.16176","article-title":"The correlation between PARP1 and BRCA1 in AR positive triple-negative breast cancer","volume":"12","author":"Luo","year":"2016","journal-title":"Int. J. Biol. Sci."},{"issue":"34","key":"10.1016\/j.jsbmb.2026.107062_bib34","doi-asserted-by":"crossref","first-page":"56364","DOI":"10.18632\/oncotarget.16913","article-title":"Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer","volume":"8","author":"Hu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jsbmb.2026.107062_bib35","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3332\/ecancer.2022.1452","article-title":"Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria","volume":"16","author":"Haruna","year":"2022","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107062_bib36","first-page":"96","article-title":"Androgen receptor expression and prognosis in Hispanic\/Latino women with triple negative breast cancer","volume":"55","author":"Melo-Uribe","year":"2022","journal-title":"Rev. Espa\u00f1ola De. Patol. \u00eda"},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107062_bib37","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/annonc\/mdq586","article-title":"Expression of androgen receptor in breast cancer and its significance as a prognostic factor","volume":"22","author":"Yu","year":"2011","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107062_bib38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00405-022-07538-w","article-title":"Bicalutamide, an androgen receptor antagonist, effectively alleviate allergic rhinitis via suppression of PI3K\u2013PKB activity","volume":"280","author":"Zhang","year":"2023","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"issue":"10","key":"10.1016\/j.jsbmb.2026.107062_bib39","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.neo.2020.07.002","article-title":"A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo","volume":"22","author":"Zhao","year":"2020","journal-title":"Neoplasia"},{"issue":"42","key":"10.1016\/j.jsbmb.2026.107062_bib40","doi-asserted-by":"crossref","first-page":"44728","DOI":"10.18632\/oncotarget.6296","article-title":"Expression of androgen receptor splice variants in clinical breast cancers","volume":"6","author":"Hickey","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107062_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41416-018-0172-0","article-title":"Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases","volume":"119","author":"Kallio","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2026.107062_bib42","unstructured":"Page D., Conlin A., Stanton S., Urba W., Redmond W., comments S full list of authors in. A phase II study of nivolumab plus ipilimumab and androgen receptor antagonist bicalutamide to stimulate thymic T cell generation in HER2-negative metastatic breast cancer [Internet]. 2023 [cited 2026 Apr 29]. Available from: \u3008https:\/\/providence.elsevierpure.com\/en\/publications\/a-phase-ii-study-of-nivolumab-plus-ipilimumab-and-androgen-recept\/\u3009."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107062_bib43","article-title":"Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into \u201cARness.\u201d","volume":"5","author":"Lim","year":"2024","journal-title":"Cell. Rep. Med."},{"issue":"15_","key":"10.1016\/j.jsbmb.2026.107062_bib44","article-title":"ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer","volume":"34","author":"Schmid","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.jsbmb.2026.107062_bib45","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1158\/1078-0432.CCR-20-1693","article-title":"A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer","volume":"26","author":"Krop","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-023-00544-z","article-title":"Phase II trial of fulvestrant plus enzalutamide in ER+\/HER2\u2212 advanced breast cancer","volume":"9","author":"Elias","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107062_bib47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41523-024-00697-5","article-title":"Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+\/Her2\u2212 breast cancer","volume":"10","author":"Elias","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"11","key":"10.1016\/j.jsbmb.2026.107062_bib48","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2026.107062_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1138","article-title":"TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician\u2019s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)","author":"Traina","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107062_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2023.103667","article-title":"Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: real-life data","volume":"73","author":"Rhanine","year":"2024","journal-title":"Breast"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026001287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026001287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:40:48Z","timestamp":1785969648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076026001287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"alternative-id":["S0960076026001287"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107062","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen receptor as therapeutic indicator for LAR-positive triple-negative breast cancer: Preclinical and clinical assessment","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107062"}}